A Randomized Phase II Trial of ARQ 197 (Tivantinib)/Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Tivantinib (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 24 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 04 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.